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The effects of repeated electroconvulsive seizures (ECS) on expression of mRNAs coding for corticotropin-releasing factor (CRF) 
and arginine vasopressin (AVP) in neuroendocrine neurons of the hypothalamo-pituitary-adrenocortical (HPA) axis and 
hypothalamo-neurohypophysial system (HNS) were assessed via semi-quantitative in situ hybridization histochemical analysis. 
Measures of mRNA content were accompanied by measurement of peptide- and hormone-expression in the relevant neuroendocrine 
systems. Following 7 daily ECS treatments, CRF mRNA was significantly increased in the medial parvocellular paraventricular 
nucleus (PVN) of treated rats relative to controls. CRF peptide content of whole PVN homogenates was decreased to 50% of control 
levels. Changes in CRF message and peptide levels were accompanied by increases in pituitary ACTH content and by elevated 
plasma corticosterone, suggesting ECS elicits long-term up-regulation of the HPA axis. AVP mRNA in the medial parvocellular 
PVN, which is known to up-regulate in response to HPA challenge by adrenalectomy, was not increased by ECS. Chronic ECS 
causes a clear up-regulation of HNS neurons of the supraoptic nucleus, characterized by increased AVP mRNA content, decreased 
AVP peptide content, and depletion of neurohypophysial AVE However, no changes were observed in magnoceilular 
vasopressinergic neurons of the PVN, indicating that magnocellular SON and PVN neurons respond differentially to stimulation 
by ECS. The data indicate that ECS is a potent stimulus for activation of select components of both the HPA axis and the HNS. 
As such, ECS provides a useful tool for examining mechanisms underlying neuroeffdocrine processes. 
INTRODUCTION 
A m o n g  the salient physiological  consequences of 
electroconvulsive seizure t rea tment  (ECS) is an 
activation of the hypotha lamo-p i tu i ta ry-adrenocor -  
tical ( H P A )  system, the principal  neuroendocr ine  
system responsible  for control  of circulating gluco- 
corticoids.  Numerous  l i terature  reports  have sug- 
gested that  in man,  ECS produces  an up-regulat ion 
of  the H P A  axis, character ized by hypersecret ion of 
p ro-op iomelanocor t in  (POMC)-de r ived  pept ides  
from the anter ior  pi tui tary gland 1"5"s'32 and gluco- 
corticoids from the adrenals  1'32. Recent ly ,  our  lab- 
o ra tory  has shown that  ECS elicits both  short-  and 
long-term up-regula t ion of the H P A  axis in the rat  32. 
Up-regula t ion  of the H P A  axis following ECS 
mimics that  seen following various stress regimens,  
indicating that  the endocr ine  effects of  ECS may be 
executed by systems governing stress regulat ion.  
It is general ly  agreed that  a ra ther  c i rcumscribed 
popula t ion  of hypotha lamic  cor t icotropin releasing 
factor (CRF)  neurons  are pr imar i ly  responsible  for 
central  integrat ion of A C T H  release (cf. ref. 2). 
These neurons,  localized to the media l  parvocel lu lar  
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subdivision of the hypothalamic paraventricular nu- 
cleus (PVN), send projections to the median 
eminence 3'26, whereby CRF is released into the 
hypophysial portal circulation upon receipt of an 
appropriate stimulus (e.g. stressor) and causes the 
release of ACTH by anterior pituitary corticotrophs 
(cf. ref. 2, for review). Following removal of 
glucocorticoid negative feedback (adrenalectomy), 
which elicits a profound increase in pituitary ACTH 
production and secretion, CRF messenger RNA 
(mRNA) and peptide content are markedly in- 
creased in medial parvocellular PVN neurons TM 
20,22,29,34 confirming a primary role for CRF in 
hypothalamic drive of the HPA axis. Adrenalecto- 
my-induced increases in CRF production and pep- 
tide expression in medial parvocellular PVN neurons 
are accompanied by a massive induction of arginine 
vasopressin (AVP) mRNA 7'31 and peptide 
expression 13"2° in CRF perikarya of the PVN, as well 
as a marked increase in colocalization of AVP and 
CRF in terminal boutons in the external lamina of 
the median eminence 3°. The importance of coex- 
pression and apparent cosecretion of AVP and CRF 
by parvocellular neurosecretory neurons is high- 
lighted by a well-documented synergistic interaction 
between CRF and AVP in promoting ACTH release 
by corticotrophs m. 
The literature summarized above supports a pu- 
tative role for CRF and AVP originating in the 
medial parvocellular PVN in neuronal regulation of 
HPA responses to physiological or psychological 
stressors. The precise role played by these ACTH 
secretagogues is presently unclear, with some im- 
portant issues in need of clarification. For instance, 
it remains to be determined whether stress results in 
long-term up-regulation of CRF production, as 
occurs following drive of the HPA axis by adrenal- 
ectomy. It is likely that repeated stress will elicit an 
increase in CRF message, in that CRF is released in 
response to a variety of stressors. However, eleva- 
tions of circulating glucocorticoids resulting from 
stressful episodes are capable of exhibiting negative 
feedback effects at multiple levels of the HPA axis H, 
including the PVN itself ~4'21. Clearly, chronic effects 
at the CRF neuron will represent an integration of 
stress activation vs feedback inhibition of this neu- 
ronal population. Along similar lines, it is not yet 
known whether induction of AVP mRNA in CRF 
neurons represents a 'physiological' amplification 
system for ACTH release by CRF under conditions 
of stress, or is primarily a concomitant of severe 
glucocorticoid depletion. In these studies, we have 
attempted to address these issues, utilizing chronic 
ECS as a model of repeated HPA activation. ECS 
was chosen as a stressor due to its ability to rapidly 
and reliably elicit widespread activation of the HPA 
axis in rats, with minimal evidence for across-trial 
habituation 32. The overall synthetic tone of PVN 
neuropeptidergic neurons was inferred from mea- 
sures of mRNA coding for AVP and CRF, using 
semi-quantitative in situ hybridization histochemis- 
try. In situ hybridization histochemistry allows pre- 
cise anatomical localization and differentiation of 
mRNA levels in tightly defined brain regions; for 
our purposes, it permits a ready differentiation 
between the effects of ECS in parvocellular vs 
adjacent magnocellular neurosecretory systems of 
the PVN in the same histological specimen. Mea- 
sures of CRF and AVP mRNA were accompanied 
by measurement of CRF content in PVN homoge- 
nates, POMC peptides in the pituitary and plasma 
and determination of plasma corticosterone, to 
verify the efficacy of ECS in inducing up-regulation 
of endocrine components of the HPA axis. 
In addition to co-expression and putative co- 
secretion of AVP and CRF in select hypothalamic 
parvocellular neurons, AVP is synthesized in neigh- 
boring magnocellular neurosecretory neurons in the 
PVN, which comprise one component of the classical 
hypothalamo-neurohypophysial system (HNS). The 
HNS secretes AVP directly into the systemic circu- 
lation, whereby its physiological effects on vascular 
smooth muscle and renal water resorption are 
conveyed. However, the effects of ECS on this vital 
neuroendocrine system remain to be characterized. 
Therefore, in the present study, in situ hybridization 
analysis of AVP mRNA expression were conducted 
on magnocellular neurons of the PVN and SON. 
Measurements of AVP mRNA were accompanied by 
determination of brain and pituitary AVP content. 
MATERIALS AND METHODS 
Subjects 
Male Sprague-Dawley rats, weighing 250-300 g 
at the time of experimentation, were housed 6 per 
cage and had ad libitum access to food and water. 
Animals were housed on a 12:12 h light:dark cycle, 
with lights on at 06.00 h. 
Treatment 
Between 09.00 and 10.30 h ECS-administered 
(ECS) rats were removed from their home cages and 
subjected to transauricular ECS (80/~A, 0.2 s, 60 
Hz). Control (CON) rats were removed from their 
home cages and replaced, receiving no ECS. ECS 
rats received treatment on each of 7 consecutive 
days. On the eighth day, 24 h following the last 
treatment, ECS and CON rats were killed by rapid 
decapitation and brains and pituitaries rapidly re- 
moved. For some subjects (6 ECS and 5 CON), 
brains were immediately frozen in liquid isopentane 
at -50 °C for in situ hybridization analysis. Addi- 
tional brains were dissected on ice to yield small 
tissue blocks containing, respectively, the PVN and 
SON for AVP and CRF radioimmunoassay. Pitu- 
itary glands from all animals were dissected into 
anterior and neurointermediate lobes and frozen on 
dry ice. Blood was collected into tubes containing 
EDTA, spun for 5 min at 1500 x g, acidified and 
frozen on dry ice until analysis. 
In situ hybridization 
Brains were sectioned at 10 /~m in a Bright 
cryostat (-20 °C), thaw-mounted onto polylysine- 
coated slides and stored at -80 °C until processed for 
in situ hybridization histochemistry. Tissue was 
sampled for in situ procedures at 50/~m intervals; an 
additional series was stained for Nissl substance with 
thionine to establish a cytoarchitectonic context for 
analysis. The in situ protocol consisted of removing 
sections directly from the -80 °C freezer and im- 
mersing them immediately in cold buffered 4% 
formaldehyde. Tissue was fixed for 1 h and washed 
3x in phosphate-buffered saline (20 mM). Sections 
were deproteinated with 0.2 N HC1 f~or 20 min at 
room temperature and washed in 2x SSC for 20 min 
prior to hybridization. 
35S-labeled RNA probes complementary to 
proAVP mRNA (T.G. Sherman; subcloned in 
pGEM4) and proCRF mRNA (courtesy R. Thomp- 
son, J. Douglass and E. Herbert; subcloned in 
pSP64) were produced using the SP6 transcription 
system (Promega). The proAVP probe was a 197 bp 
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cRNA coding for the C-terminal region of the 
proAVP molecule, which bears no homology with 
proOxytocin. The proCRF probe was a 353 bp 
cRNA derived from a rat CRF cDNA clone, 
including the peptide coding region (exon 2) of the 
rat CRF gene. 35S-labeled and unlabeled S-UTP was 
added to the transcription reaction in amounts 
calculated to yield specific activities estimated at 
0.94 x 104 Ci/mmol probe and 2.54 x 10 4 Ci/mmol 
probe for AVP and CRF cRNA probes, respectively. 
Probe was diluted in a standard hybridization 
buffer (75% formamide, 10% dextran sulfate, 3× 
SSC, 50 mM sodium phosphate buffer, pH 7.4, 1 × 
Denhardt's, 0.1 mg/ml yeast tRNA and 0.1 mg/ml 
sheared salmon sperm DNA) sufficient to yield 
2,000,000 dpm/30/~1 buffer. 30/~1 aliquots were then 
applied to each slide, the slides coverslipped, and 
coverslips sealed with rubber cement. Slides were 
placed in plastic boxes containing moistened foam 
and the boxes sealed. Sections were incubated at 
55 °C for 48 h, at which time coverslips were 
removed, the slides rinsed in 2x SSC and immersed 
in fresh 2x SSC for 20 min. Tissue was then reacted 
with RNAse A (200/~g/ml) at 37 °C for 30 min to 
degrade any remaining single-stranded RNA. Sec- 
tions were then washed successively in 2x ,  1× and 
0.5x SSC for 10 min each, followed by a 1 h wash 
in 0.5× SSC at the hybridization temperature. 
Sections were then exposed to Kodak XAR X-ray 
film overnight, and subsequently emulsion-dipped, 
along with slide-mounted brain-paste standards con- 
taining known amounts of 35S-labeled L-methionine, 
in Kodak NTB2 nuclear emulsion. Emulsion-dipped 
sections and standards were exposed for 10 days 
(AVP) or 3 weeks (CRF), with final batch develop- 
ment based on grain densities of dipped slides 
developed at regular intervals. 
Image analysis 
Semi-quantitative analysis of in situ hybridization 
autoradiographs was conducted utilizing Loats image 
analysis software. Analysis was performed on 6 ECS 
and 5 CON animals, using 8.2 + 0.4 PVN sections/ 
animal for CRF analysis of the PVN, and 12.7 + 1.5 
PVN sections/animal for AVP analysis of the PVN, 
and 22.7 + 2.1 sections/animal for AVP analysis of 
the SON. Emulsion-dipped sections and 35S-labeled 
standards of known radioactivity were digitized and 
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subjected to areal analysis of optical density over the 
areas of interest in the images, those being the 
medial parvocellular and immediately adjacent pos- 
terior magnocellular divisions of the PVN and the 
SON. The image analytic scheme is presented in Fig. 
1, which illustrates the criteria used to select appro- 
priate regions of interest. Briefly, quantified areas 
Fig. 1. Example illustrating the analytical scheme employed 
for semi-quantitative in situ hybridization analysis of AVP and 
CRF mRNAs in the paraventricular nucleus. Shown are 
neighboring sections from the same animal, one stained for 
Nissl substance with thionine (upper panel) and the other 
hybridized with an antisense RNA probe for AVP mRNA 
(lower panel). Sections are separated by 30/~m. At this level 
of the PVN, posterior magnocellular (PM) and medial parvo- 
cellular (rap) divisions were defined (as shown) from Nissl- 
stained sections and the corresponding regions outlined on 
digitized images of autoradiographs by a manually operated 
cursor, using a polygonal sampling mode (illustrated in upper 
panel). Care was taken to avoid including the dorsal parvo- 
cellular (dp) PVN, lateral parvoceUular (lp) PVN or periven- 
tricular zone (pz) in the sampling procedure. Background 
regions were digitzed over cellular regions distinct from the 
PVN and free from any evidence of positive hybridization 
signal (bck). 
were defined on the basis of PVN and SON 
cytoarchitecture (based on parallel Nissl-stained 
series) and by patterns of grain localization within 
the section of interest. Determination of disintegra- 
tion values for areas selected was derived from a 
standard curve of best fit relating optical density 
values of the digitized images of 35S-labeled stan- 
dards with corresponding disintegration values. Ra- 
dioactivity of standards was determined by counting 
adjacent standard sections in a Beckman beta coun- 
ter, and subsequent dpm values corrected for time of 
exposure and area of standard. The optical density 
of all samples fell within the range of the standard 
values. 
For statistical analysis, Nissl-stained sections were 
used to group SON and PVN sections from individ- 
ual animals into different anatomical levels, using 
the Paxinos and Watson coordinate system TM. For the 
SON, coronal sections were grouped into 1 of 4 
levels, corresponding to ranges spanning 1000-1200, 
1200-1400, 1400-1600, and 1600-1800 pm posterior 
to bregma. For the magnocellular PVN, sections 
were grouped into 4 levels corresponding to ranges 
spanning 1600-1700, 1700-1800, 1800-1900, and 
1900-2000 ktm posterior to bregma. As both parvo- 
cellular CRF and AVP mRNA-containing neurons 
were widely scattered at the 1900-2000 pm level, 
quantitative data are not reported for this region in 
analysis of the parvocellular PVN. 
Radioimmunoassay 
Radioimmunoassay for AVP in PVN, SON and 
neurointermediate lobe (NIL) was performed ac- 
cording to previously published methods 25. PVN and 
SON punches were diluted 1/1000 in assay buffer for 
analysis, and NIL samples 1/10,000. The minimal 
detectable amount of AVP was 1 pg/assay tube. 
Cross-reactivity with oxytocin was 0.02%. 
For CRF radioimmunoassay, a single 50 pl and 
duplicate 25 pl aliquots of PVN and SON homoge- 
nates were tested. The antibody to CRF was gen- 
erously provided by Dr. John Olschowka, University 
of Rochester. It was raised in rabbits against a 
conjugate of human/rat CRF and bovine thyroglob- 
ulin (antiserum 455 (ref. 16)) and used at a final 
dilution of 1/1,500,000. The assay buffer was 0.1 M 
phosphate-buffered saline containing 0.5% bovine 
serum albumin (pH 7.6). Synthetic CRF (Peninsula) 
was used as the standard. 125I-CRF (Amersham,  
5000 cpm) was added to the assay mixture after 24 
h of  incubation at 4 °C. Following an additional 72 
h of  incubation, ant ibody-bound CRF  was separated 
from unbound CRF  by the addition of  1 ml of  95% 
cold ethanol and subsequent centrifugation (3000 
rpm, 4 °C, 45 min). The supernatant was discarded 
and the pellets containing bound tracer were 
counted in a gamma counter. In the absence of  CRF, 
the assay conditions resulted in binding of  45% of 
the tracer. The assay has a minimum detection limit 
of  5 pg per assay tube, the ICso was 32 pg per assay 
tube, and the intra-assay coefficient of variation was 
4.5%. All samples for CRF  content were evaluated 
in the same assay. Lack of  cross-reactivity of  this 
antibody with a variety of  peptides has been dem- 
onstrated previously 16. 
Radioimmunoassay of  A C T H  was performed on 
anterior pituitary samples. Plasma samples were 
extracted prior to assay with Sep-Pak Cxs cartridges 
as previously described 6 and subsequently assayed 
for fl-endorphin immunoreactivity. Both radioimmu- 
noassays and antibodies have been described pre- 
viously 33. Some aspects of  the fl-endorphin assay 
deserve comment .  The fl-endorphin antibody 
(Brenda) is a mid-portion antibody raised against 
f l-endorphin(1-31).  It was used at a final dilution of  
1/40,000. [125I]fl-endorphin (human) was used as the 
radiolabeled tracer, f l-endorphin(1-31) (camel) was 
used for construction of  a standard curve. Under  
these conditions, this antibody shows 100% cross- 
reactivity with fl-lipotropin, 80% cross-reactivity 
TABLE I 
HPA axis hormones and peptides: effects of ECS 
Control ECS 
Pituitary ACTH 
(pmol/gland) 122 + 7 (7) 210 + 16 (7) . . . .  
Plasma fl-endorphin 
(fmol/ml) 71 + 12 (12) 55 + 11 (11) 
Plasma corticosterone 
~g/di) 3.3 + 1.1 (18) 7.5 + 1.1 (17)** 
* Values represent mean _+ standard error of the mean; 
numbers in parentheses represent number of animals/ 
group. 
** Significantly different from control, P < 0.05, two-tailed 
t-test. 
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with N-acetylated fl-endorphin(1-31) and 50% 
cross-reactivity with N-acetylated f l -endorphin(1-  
27), the primary species of  fl-endorphin secreted by 
rat intermediate lobe. Previous studies from our  
laboratory indicate that plasma fl-endorphin values 
obtained using this antibody reliably parallel A C T H  
levels 33. 
Plasma corticosterone was measured using a 
standard competitive protein binding assay 17, using 
[3H]corticosterone as the radiolabeled tracer. 
RESULTS 
Hypothalamo-pituitary-adrenocortical axis 
Table I summarizes the effects of  ECS on hor- 
monal components  of  the H P A  axis 24 h after the 



























Fig. 2. In situ hybridization histochemical analysis of cortico- 
tropin releasing factor (CRF) mRNA (A) and arginine 
vasopressin (AVP) (B) in the medial parvocellular subdivision 
of the hypothalamic PVN. The medial parvocellular subdivi- 
sion was divided into 3 levels for analysis, with level A 
including sections from 1600-1700/tm, level B sections from 
1700-1800/~m, and level C sections 1800-1900/zm posterior to 
bregma, using the coordinate system of Paxinos and Watson. 
CRF mRNA showed a clear-up regulation in response to ECS, 
showing increased expression across the entire medial parvo- 
cellular PVN (overall group effect: F 1 , 2 6  = 6.81, P < 0.02). In 
contrast, AVP mRNA did not change following ECS. 
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Fig. 3. Autoradiographs of representative emulsion-dipped sections through the PVN of ECS (A,C) and control (B,D) rats, 
hybridized with 35S-labeled cRNA probes complementary to AVP (A,B) and CRF (C,D) mRNA. All sections are from 
approximately the same rostrocaudal level (PVN level B). In A and B, it is evident that no substantial differences in hybridization 
density can be detected between the ECS (A) and control (B) groups in either the posterior magnocellular PVN (pm) or the medial 
parvocellular PVN (mp). Cells scattered in the medial parvocellular PVN probably represent scattered magnocellular neurons 
normally present in this region. In C and D, however, an increase in hybridization signal for CRF mRNA is evident in ECS (C) 
sections relative to control (D) tissue. Positive hybridization signal for CRF mRNA is primarily associated with the medial 
parvocellular subgroup of the PVN. Magnification bar = 100/~m. 
pept ides  in pi tui tary and plasma revealed a signifi- 
cant increase in pi tui tary A C T H  content  in the ECS 
group 012 = 5.64, P < 0.001), indicative of an 
increased synthesis/storage of POMC-der ived  pep- 
tides in the anter ior  pituitary.  Circulating fl-endor- 
phin did not differ significantly between the two 
groups,  indicating that  pept ide  levels had re turned to 
resting values. Yet, p lasma cort icosterone levels 
were significantly increased in animals receiving 
ECS relative to handled  controls (t33 = 2.67, P < 
0.02), suggesting a long-term potent ia t ion of adre-  
nocort ical  glucocort icoid secretion. 
Results  of quanti tat ive in situ analysis for AVP 
and C R F  m R N A s  are shown in Fig. 2. Neurosecre-  
tory neurons of the H P A  axis undergo an up- 
regulat ion in response to ECS,  as evident  from a 
significant increase in C R F  m R N A  across the 3 
levels of the medial  parvocel lu lar  PVN sampled 
(F1.26 = 6.81, P < 0.02) (Fig. 2). AVP m R N A  
content  across the same 3 levels of the medial  
parvocel lular  PVN was, however ,  unaffected by 
ECS (Fig. 2). Nei ther  C R F  nor  A V P  m R N A  varied 
as a consequence of region of the PVN sampled.  
Autorad iographs  of labeled C R F  and AVP 
m R N A  in the medial  parvocel lular  PVN in the ECS 
and C O N  groups are i l lustrated in Fig. 3. Qual i ta t ive  
differences can be observed  be tween ECS and CON 
rats in overall  densi ty of C R F  m R N A  labeled over  
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TABLE II 
Hypothalamic and pituitary CRF content 
Control ECS 
PVN (fmol/nucleus) 49.8 + 0.2 (6) 26.1 + 6.7 (6)*'** 
SON (fmol/nucleus) 23.1 + 3.4 (6) 30.1 + 6.5 (6) 
NIL (fmol/pituitary lobe) 59.2 + 7.6 (6) 67.4 + 3.8 (6) 
* Values represent mean + standard error of the mean; 
numbers in parentheses represent number of animals/ 
group. 



























Fig. 4. In situ hybridization histochemical analysis of arginine 
vasopressin (AVP) (B) in magnocellular nuclei comprising the 
hypothalamo-neurohypophysial system, including the su- 
praoptic nucleus (SON) (A) and the posterior magnocellular 
subdivision of the paraventricular nucleus (PVN) (B). The 
SON was divided into 4 levels for analysis: level A included 
sections between 1000 and 1200 am, level B, sections between 
1200 and 1400/am, level C, sections between 1400 and 1600 
/am, and level D, sections between 1600 and 1800/am posterior 
to bregma, using the Paxinos and Watson coordinate system. 
Over all SON levels, AVP mRNA was significantly increased 
in the ECS group relative to controls (significant group effect: 
F1.33 = 6.88, P < 0.02). Differences were particularly 
pronounced over levels B and C, which contain the densest 
populations of AVP neurons. The posterior magnoceilular 
PVN was divided also into four levels, with level A including 
sections from 1600 to 1700/am, level B sections from 1700 to 
1800/am, and level C sections 1800 to 1900/am, and level D 
sections from 1900 to 2000/am posterior to bregma. In contrast 
to the SON, no change in AVP mRNA was observed in this 
neuronal population following chronic ECS treatment. 
Fig. 5. Autoradiographs of representative emulsion-dipped 
sections through the SON of ECS (A) and control (B) rats, 
hybridized with 35S-labeled cRNA probes complimentary to 
AVP mRNA. Both sections are taken from approximately the 
same rostrocaudal level (SON level C). A considerably more 
dense hybridization signal is observed over the SON of ECS 
tissue when compared with sections from control rats. Mag- 
nification bar = 100/am. 
the  P V N  (Fig. 3 C , D ) .  H o w e v e r ,  no  changes  in A V P  
m R N A  were  o b s e r v e d  in the  med ia l  pa rvoce l lu l a r  
zone  o f  the  P V N  (Fig.  3 A , B ) .  T h e r e  is no  ev idence  
to suggest  an induc t ion  o f  A V P  m R N A  in med ia l  
pa rvoce l lu la r  P V N  neu rons ;  mos t  pos i t ive ly  l abe led  
cells seen  sca t t e red  t h r o u g h o u t  this a rea  are  i so la ted  
magnoce l l u l a r  neu rons  (based  on  n e u r o n a l  size and 
dens i ty  of  hybr id iza t ion ,  ut i l iz ing phase -con t r a s t  
mic roscopy) .  
R a d i o i m m u n o a s s a y  for  C R F  p e p t i d e  in h o m o g e -  
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nates of the PVN region (Table II) indicate that 
chronic ECS elicits a decrease in CRF in the PVN 
(tl0 = 3.39, P < 0.01). No changes were observed in 
AVP content of the PVN; however, it should be 
noted that homogenates of the PVN sample both the 
magnocellular and parvocellular PVN, and given the 
overwhelming preponderance of AVP in magnocel- 
lular neurons it is unlikely that any change in 
parvocellular content would be detectable. 
Hypothalamo-neurohypophysial system 
Examination of magnocellular nuclei comprising 
the hypothalamo-neurohypophysial system revealed 
an interesting and somewhat divergent pattern of 
changes following chronic ECS (Fig. 4). AVP 
mRNA content in the 4 sampled regions of the 
posterior magnocellular subdivision of the PVN was 
not changed by ECS. However, AVP mRNA con- 
tent was significantly increased across the SON 
regions sampled (F1,33 = 6.88,  P < 0.02) (Fig. 4). 
Enhancement of SON AVP mRNA levels following 
ECS was most pronounced in levels B and C, 
corresponding to regions of the SON where AVP is 
particularly abundant. 
Autoradiographs of sections hybridized with la- 
beled antisense AVP cRNA probes for the ECS and 
CON groups are presented in Figs. 3 and 5. As seen 
in Fig. 3A,B, AVP mRNA does not appear in- 
creased in the posterior magnocellular division of the 
PVN in the ECS group relative to controls. In 
contrast with the magnocellular PVN, marked in- 
creases in detected AVP mRNA can be observed in 
the SON of ECS animals (Fig. 5). 
CRF mRNA was present only in scattered neu- 
rons of the SON and magnocellular divisions of the 
TABLE III 
Hypothalamic and pituitary vasopressin content 
Control ECS 
PVN (pmol/nucleus) 6.2 + 0.9 (18) 5.2 _+ 0.8 (13)* 
SON (pmol/nucleus) 20.6 + 1.9 (17) 14.0 + 1.0 (13)** 
NIL (pmol/pituitary lobe) 878 + 34 (29) 636 +_ 38 (26)** 
* Values represent mean + standard error of the mean; 
numbers in parentheses represent number of animals/ 
group. 
** Significantly different from control, P < 0.05, two-tailed 
t-test. 
PVN, and was not quantifiable using areal density 
measures. No qualitative differences were evident 
between the ECS and CON groups in magnocellular 
CRF mRNA content. 
Radioimmunoassay for AVP in homogenates of 
the PVN and SON suggest that AVP peptide is 
regulated differentially in the two nuclei following 
ECS (Table III). AVP peptide was significantly 
decreased in the SON of ECS rats relative to control 
animals (t28 = 2.76, P < 0.01), while no changes in 
peptide content were observed in PVN. Content of 
AVP in the NIL was significantly diminished in the 
ECS group (t53 = 4.75, P < 0.001), indicating an 
apparent long-term depletion of neurohypophysial 
stores in response to ECS. In contrast to changes in 
neurohypophysial AVP, CRF immunoreactivity did 
not change in the SON or NIL following ECS. 
DISCUSSION 
Results of this study indicate that chronic ECS 
effects an up-regulation in neurons regulating acti- 
vation of the HPA axis. CRF mRNA content is 
increased by approximately 40% in the medial 
parvocellular PVN of the ECS group. In combina- 
tion with decreases in PVN CRF content, the data 
suggest that PVN CRF neurons are in a state of 
accelerated production and release of CRF as a 
result of chronic ECS. The significant changes in 
CRF peptide content and CRF mRNA levels are 
accompanied by significant elevations of pituitary 
ACTH stores and circulating corticosterone. The 
long-term augmentation of CRF mRNA production, 
in the face of elevated glucocorticoid levels, suggests 
that the CRF neuron plays an important role in 
maintaining activation of the HPA axis under con- 
ditions of chronic stress. Elevated glucocorticoid 
levels appear unable to return CRF mRNA expres- 
sion to normal, indicating that CRF gene expression 
may be controlled by sources other than, or in 
addition to, circulating glucocorticoids following 
chronic challenge with ECS. 
The observed increase in CRF mRNA expression 
probably represents a summation of conflicting 
physiological information stemming from competi- 
tion between the repeated drive of CRF neurons by 
ECS and inhibition of CRF gene expression by 
glucocorticoids. An analogous situation occurs with 
the POMC gene upon chronic stress; increased drive 
of the pituitary leads to initiation of POMC mRNA 
expression, while increased glucocorticoid secretion 
inhibits transcription, leading to a relatively small 
(30%) overall increase in anterior pituitary POMC 
mRNA 24. Interestingly, chronic stress results in a 
two-fold increase in anterior pituitary POMC pep- 
tide stores 24 and increased releaseability of POMC 
peptides 33, indicating that the limited increase in 
mRNA in the POMC system may be of considerable 
physiological significance. These data, coupled with 
the ability of the HPA axis to physiologically 
'amplify' signals at successive points between brain 
and adrenal, underline the potential for relatively 
small changes in brain CRF mRNA to profoundly 
influence the overall tone of the HPA axis. 
CRF mRNA in the medial parvocellular PVN of 
ECS rats was consistently greater than control at all 
anterior-posterior levels of the nucleus examined. 
These data indicate that CRF induction by ECS does 
not topographically select any individual area of 
PVN, and thus that in response to the chronic ECS 
stimulus, medial parvocellular CRF neurons may act 
in concert to stimulate the HPA axis. 
In contrast with the observed elevation of CRF 
mRNA content, no change was seen in AVP mRNA 
content in the medial parvocellular PVN, where 
AVP is co-localized with CRF following removal of 
circulating steroids 13'2°'31. The lack of an induction 
of AVP in medial parvocellular PVN neurons implies 
that chronic ECS does not recruit production of 
AVP in this neuronal population. The failure of ECS 
to induce AVP mRNA in CRF-containing nuclei 
suggests either (1) that the AVP induction in these 
neurons is critically dependent on circulating gluco- 
corticoid levels rather than neuronal stimulation, 
and hence will not occur under conditions of normal 
or elevated glucocorticoids, (2) that the drive of the 
HPA axis by ECS was not sufficient to elicit 
long-term up-regulation of parvocellular AVP neu- 
rons, or (3) that parvocellular PVN AVP induction 
may be physiologically associated with acute  stress 
responses, and rapidly returns to baseline following 
removal of the stressor (perhaps as a result of 
glucocorticoid feedback). 
It should be noted that although the data do not 
demonstrate significant changes in parvocellular 
AVP mRNA under conditions of chronic stress, the 
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possibility remains that the in situ hybridization 
procedure employed is not sufficiently sensitive to 
detect changes in AVP-producing cells in this region. 
For instance, small changes may be undetectable 
either due to a level of expression which is beneath 
the detection limits imposed by the selected in situ 
hybridization conditions, or to increased variability 
imposed by scattered magnocellular neurons local- 
ized within the medial parvocellular PVN. The 
physiological relevance of any such undetectably 
small change in AVP mRNA should not be sum- 
marily dismissed, given the known synergism be- 
tween CRF and AVP in promotion of ACTH 
release 1°. 
Chronic ECS also provides a significant stimulus 
to the hypothalamo-neurohypophysial system 
(HNS), as is evident from a significant increase in 
SON AVP mRNA. The increase in SON AVP 
message is particularly pronounced over levels B and 
C, regions known to be particularly rich in AVP- 
containing magnocellular neurons 19. Activation of 
the HNS is further corroborated by the observed 
depletion of NIL AVP peptide, suggesting that this 
stimulus serves to promote extensive release of 
secretable pools of AVP at the neurohypophysial 
vasculature. The decrease in SON peptide content in 
ECS animals, in conjunction with neurohypophysial 
depletion and increased SON AVP mRNA levels, 
indicates that AVP is being rapidly synthesized and 
perhaps rapidly released by SON neurons. Activa- 
tion of the SON component of the HNS by ECS 
suggests a hypersecretion of AVP into the circula- 
tion, perhaps contributing to increases in arterial 
blood pressure seen following ECS 4. One of the 
most striking points to be made about up-regulation 
of SON AVP neurons is the chronic nature of this 
effect: perikaryal and terminal depletion and in- 
creased AVP mRNA synthesis are occurring 24 h 
following the last ECS. Continued synthesis and 
release of AVP following cessation of ECS may 
reflect a characteristic response of magnocellular 
neurosecretory neurons to chronic stimulation; pre- 
vious studies indicate that while plasma osmolality 
returns to normal fairly quickly following cessation 
of chronic osmotic stimulation (salt loading), hypo- 
thalamic and pituitary AVP content and hypotha- 
lamic AVP mRNA take considerably longer to 
return to baseline levels 35. These data seem to 
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indicate that the HNS maintains high rates of 
peptide synthesis for a substantial time period 
following stimulation, perhaps to replenish depleted 
pituitary stores. 
Perhaps more perplexing than the chronic in- 
crease in SON AVP mRNA content is the apparent 
lack of any observable effect of ECS on AVP mRNA 
or AVP peptide levels in magnocellular PVN neu- 
rons. This neuronal population, like that of the 
SON, is believed to project predominantly to the 
neurohypophysis, where it is involved primarily with 
fluid and electrolyte balance. In addition, neuronal 
afferents to SON and magnocellular PVN are re- 
markably similar in scope and magnitude 27. Al- 
though it has been documented that the SON 
contains a considerably greater number of AVP 
neurons and correspondingly greater amounts of 
AVP 9"19, it is reasonable to expect that functionally 
related AVP neurons of the PVN should experience 
an up-regulation of similar magnitude. The apparent 
discrepancy in AVP mRNA expression between 
magnocellular PVN and SON neurons in response to 
ECS represent a rather novel indication of differen- 
tiation between neurons commonly held to be a 
functionally homogeneous pool. While this discrep- 
ancy is difficult to explain given the input-output 
systems and common function of the two nuclei, two 
salient differences between the SON and PVN may 
lie at the core of this phenomenon. First, unlike 
magnocellular PVN neurons, SON AVP neurons 
appear to retain a significant population of gluco- 
corticoid neurons 12. In that glucocorticoids are in- 
creased by chronic ECS, as shown above, genomic 
effects of internalized glucocorticoids may be suffi- 
cient to induce long-term changes in synthesis and 
perhaps release of AVP by SON neurons. Secondly, 
SON neurons are localized close to the surface of the 
brain. If the depolarizing stimulus is propagated 
along the surface of the brain with a greater intensity 
than that in deeper structures, the cell-body depo- 
larization occurring in SON neurons may be signifi- 
cantly greater than that of PVN neurons, yielding an 
effectively more intense stimulus for release. 
CRF peptide content in the SON or NIL is not 
affected by ECS. Combined with a failure to observe 
substantial increases in CRF mRNA in SON, these 
data indicate that CRF and AVP are differentially 
regulated in the hypothalamo-neurohypophysial sys- 
tem. These observations agree with anatomical data 
showing colocalization of CRF in oxytocin but not 
AVP-containing magnocellular neurons 27. Interest- 
ingly, it is well-known that oxytocin neurons are 
osmotically sensitive and that both oxytocin and 
CRF mRNAs increase dramatically in the SON upon 
chronic salt loading 15. The lack of change in SON 
CRF mRNA,  accompanied by the relatively limited 
increase in AVP mRNA in this region (in compar- 
ison to 8-10 fold changes seen following osmotic 
stimulation) 23, suggest that stimulation provided by 
ECS is modest with respect to the dynamic range of 
response available to neurons associated with the 
HNS. 
Increases in pituitary ACTH and plasma cortico- 
sterone following ECS strongly mimic changes in 
HPA axis function seen with chronic stress 24, and 
accent the value of ECS as a model of chronic stress. 
ECS has significant advantages over other stress 
paradigms, in that it is a relatively short-lived 
stressor which produces long-lasting endocrine 
changes comparable in magnitude with more pro- 
longed stress regimens. In addition, the combined 
observations of involvement of the HPA axis in 
human depressive illness es and the well-known effi- 
cacy of ECS as remedial treatment for major 
depression suggest that interactions between depres- 
sion and the HPA axis may hinge on processes 
susceptible to influence by ECS, and mandate 
further characterization of effects of ECS on neu- 
roendocrine systems. 
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